News | August 21, 2025
NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Rivaroxaban is used to treat venous thromboembolism
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
